Biodexa Pharmaceuticals PLC
NASDAQ:BDRX

Watchlist Manager
Biodexa Pharmaceuticals PLC Logo
Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
Watchlist
Price: 2.45 USD -2.39% Market Closed
Market Cap: 1.5m USD

Biodexa Pharmaceuticals PLC
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biodexa Pharmaceuticals PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
Cash from Operating Activities
-ÂŁ12.3m
CAGR 3-Years
-27%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Operating Activities
-$142.1m
CAGR 3-Years
-2%
CAGR 5-Years
-89%
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash from Operating Activities
-$254.2m
CAGR 3-Years
-33%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Operating Activities
ÂŁ26.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Operating Activities
ÂŁ67.2m
CAGR 3-Years
25%
CAGR 5-Years
2%
CAGR 10-Years
7%
Oxford BioMedica PLC
LSE:OXB
Cash from Operating Activities
-ÂŁ7.8m
CAGR 3-Years
28%
CAGR 5-Years
-6%
CAGR 10-Years
3%
No Stocks Found

Biodexa Pharmaceuticals PLC
Glance View

Market Cap
1.5m USD
Industry
Biotechnology

Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 27 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The firm is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.

BDRX Intrinsic Value
Not Available

See Also

What is Biodexa Pharmaceuticals PLC's Cash from Operating Activities?
Cash from Operating Activities
-12.3m GBP

Based on the financial report for Dec 31, 2024, Biodexa Pharmaceuticals PLC's Cash from Operating Activities amounts to -12.3m GBP.

What is Biodexa Pharmaceuticals PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-14%

Over the last year, the Cash from Operating Activities growth was -80%. The average annual Cash from Operating Activities growth rates for Biodexa Pharmaceuticals PLC have been -27% over the past three years , -14% over the past five years .

Back to Top